Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01454102
Title Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Ucla Los Angeles California 90095 United States Details
Yale University New Haven Connecticut 06520 United States Details
H. Lee Moffitt Cancer Center & Research Institute Tampa Florida 33612 United States Details
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland 21287 United States Details
Memorial Sloan Kettering Nassau New York New York 10065 United States Details
Duke University Medical Center Durham North Carolina 27710 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
Ut Southwestern Medical Center At Dallas Dallas Texas 75390-8852 United States Details
University of Washington - Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
Local Institution Hamilton Ontario L8V 5C2 Canada Details
Local Institution Ottawa Ontario K1H 8L6 Canada Details
Local Institution Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field